Antihyperglycemics (SGLT2 inhibitors)
- T2DM drugs with major HF/renal benefit
- Benefits extend beyond glucose lowering
- HF/CKD: empa/dapagliflozin lead
- Modest weight + BP reduction
- Genital mycosis + volume depletion
- Rare euglycemic DKA; hold with fasting
- Glycemic effect wanes at low eGFR
- Can lower serum lithium
Class at a glance
- T2DM drugs with major HF/renal benefit
Clinical role
- Benefits extend beyond glucose lowering
- HF/CKD: empa/dapagliflozin lead
- Genital mycosis + volume depletion
Members / distinctions
- Rare euglycemic DKA; hold with fasting
- Glycemic effect wanes at low eGFR
- Can lower serum lithium
Practical pearls
- Modest weight + BP reduction
Self-check
- What is the key clinical organizing principle for Antihyperglycemics (SGLT2 inhibitors)?
T2DM drugs with major HF/renal benefit.
Drugs in this class (5)
All drug classes · Open the interactive console ↗
